FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.
Asset / Drug
Drug and asset intelligence for Tecentriq with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.